Akebia Therapeutics, Inc. - Common Stock (NQ:AKBA)

0.8815 -0.0290 (-3.19%)

Delayed Quote Updated: 2:41 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Akebia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More ↗

March 27, 2022

Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.

Via Benzinga

Bronstein, Gewirtz & Grossman, LLC Notifies Akebia Therapeutics, Inc. (AKBA) Shareholders of Class Action and Encourages Investors to Contact the Firm

March 22, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Earnings Scheduled For March 1, 2022 ↗

March 01, 2022

Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated...

Via Benzinga

ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA

March 21, 2022

From The Rosen Law Firm, P.A.

Via Business Wire

AKEBIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Akebia Therapeutics, Inc. and Encourages Investors to Contact the Firm

March 17, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

AKBA EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AKBA

March 15, 2022

From Rosen Law Firm

Via Business Wire

7 Biotech Stocks With Key Catalysts in March ↗

March 09, 2022

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways.

Via InvestorPlace

Akebia Therapeutics Earnings Perspective: Return On Capital Employed ↗

March 03, 2022

Benzinga Pro data, Akebia Therapeutics (NASDAQ:AKBA) reported Q4 sales of $59.60 million. Earnings fell to a loss of $70.68 million, resulting in a 18.7% decrease from last...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates ↗

March 02, 2022

The Food and Drug Administration approval calendar was light in February. Nevertheless, the month saw regulatory nods accorded to some breakthrough therapies. Agios...

Via Benzinga

Recap: Akebia Therapeutics Q4 Earnings ↗

March 01, 2022

Akebia Therapeutics (NASDAQ:AKBA) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

7 Speculative Penny Stocks Worth a Roll of the Dice ↗

February 25, 2022

Under any circumstance, penny stocks are extremely risky. However, their under-the-radar profile could be intriguing right now.

Via InvestorPlace

The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development ↗

February 23, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...

Via Benzinga

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Akebia Therapeutics, Inc. (AKBA) Investigation

January 27, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)

January 19, 2022

Via AB Newswire

Topics Bonds Stocks

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

January 04, 2022

Gainers Oncternal Therapeutics (NASDAQ:ONCT

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 30, 2021

Gainers Kiora Pharmaceuticals (NASDAQ:KPRX) stock moved upwards by 20.4% to $1.06 during Thursday's pre-market session. The market value of their outstanding shares is...

Via Benzinga

Akebia Therapeutics, inc (AKBA) Q3 2021 Earnings Call Transcript ↗

November 09, 2021

AKBA earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

After FDA Rejection, EMA Approves FibroGen-Astellas' Roxadustat ↗

August 20, 2021

The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN) and Astellas Pharma's (OTC: ALPMF) Evrenzo (roxadustat) for anemia caused by...

Via Benzinga

99 Biggest Movers From Yesterday ↗

August 06, 2021

Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...

Via Benzinga

Akebia Therapeutics, inc (AKBA) Q2 2021 Earnings Call Transcript ↗

August 05, 2021

AKBA earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Why Akebia Therapeutics Stock Is Soaring Today ↗

August 05, 2021

Investors liked what they heard in the company's Q2 update.

Via The Motley Fool

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm

July 27, 2021

From The Schall Law Firm

Via Business Wire

SHAREHOLDER ALERT: Robbins LLP Announces that Akebia Therapeutics, Inc. (AKBA) is Being Sued for Misleading Keryx Biopharmaceuticals, Inc. (KERX) Shareholders Ahead of Merger

July 26, 2021

From Robbins LLP

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

July 16, 2021

Gainers Moderna (NASDAQ:MRNA) stock increased by 7.67% to $279.6 during Friday's pre-market session. The company's market cap stands at $112.2 billion. Eton...

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 15, 2021

Gainers Akebia Therapeutics (NASDAQ:AKBA...

Via Benzinga

Akebia Therapeutics Insights: Return On Capital Employed ↗

June 21, 2021

During Q1, Akebia Therapeutics (NASDAQ:AKBA) brought in sales totaling $52.30 million. However, earnings decreased 23.97%, resulting in a loss of $64.94 million. In Q4, Akebia...

Via Benzinga

June 18, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Lawsuit

Cramer Gives His Opinion On Novavax, Exact Sciences And More ↗

June 08, 2021

On CNBC's "Mad Money Lightning Round," Jim Cramer said he prefers Moderna Inc (NASDAQ: MRNA) over Novavax, Inc. (NASDAQ: NVAX). Philip Morris International Inc. (...

Via Benzinga

Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise ↗

June 04, 2021

Cyclerion Therapeutics Inc (NASDAQ: CYCN) has entered into an exclusive, global license agreement with Akebia Therapeutics Inc (NASDAQ: AKBA) for the...

Via Benzinga

Looking Into Akebia Therapeutics's Return On Capital Employed ↗

June 01, 2021

During Q1, Akebia Therapeutics (NASDAQ:AKBA) brought in sales totaling $52.30 million. However, earnings decreased 23.97%, resulting in a loss of $64.94 million. Akebia...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.